In the wake of Brexit, the pharma industry will need to respond to a new regulatory landscape. Peter Morgan discusses how businesses have to prepare for the oncoming political changes, all whist retaining high pharmaceutical product quality.
As the end of 2019 approaches, the pharmaceutical industry is no closer to really understanding the impact of the UK’s planned departure from the EU than they were when the referendum was held in June 2016.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
Almost nine months on from the original planned date of Brexit, the UK’s strategy for leaving the EU – and the consequences this will bring in terms of trans-European trade and product regulation – remains nebulous and definitive answers are unlikely to be forthcoming until after the general election on 12 December at the very earliest. However, for drugmakers in the UK, Europe and beyond, waiting this long to make preparations for all contingencies is not a viable option.
For many years, elemental analysers have provided manufacturers with a reliable method of analysing the microbial integrity of the drugs they create”
Should Brexit go ahead at the end of January 2020 as planned, this will inevitably bring about major changes to the way pharmaceuticals are tested, analysed and regulated within the UK and European markets. Given the pivotal importance of established quality assurance methodologies in the field of medicine, manufacturers need to be doing all they can to ensure their internal QC standards are robust enough to withstand any challenges Brexit may bring.
How will Brexit affect the regulation of medicines?
Rigorous quality assurance processes are pivotal for any major commercial industry, but the stakes are higher for pharmaceuticals, where proper product testing can make the difference between life and death.
The stringent regulations and high standards required in the pharmaceutical sector are among the key reasons why patients and medical professionals are able to place so much trust in their products. As such, the prospect of Brexit bringing an end to regulatory consistency and continuity within the European pharmaceuticals market poses a potentially significant challenge.
It has already been made clear that the UK’s departure from the EU will remove the British drug market from the jurisdiction of the European Medicines Agency (EMA), with marketing authorisations delivered through the EMA’s centralised approvals procedure ceasing to be applicable in the UK market. Steps have already been taken to lay the groundwork for this change; most notably, the headquarters of the EMA, formerly based in London, have been moved to Amsterdam in anticipation of Brexit.
However, the structure of the post-Brexit medicine testing and approvals process is yet to be confirmed. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA), which currently works within the EMA’s EU-wide governance network, is primed to become the primary regulator for this industry in Britain, but the details of how this will work in practice are unclear; in the meantime, the MHRA has been cut out of the EMA’s drug approval and oversight processes.
Elsewhere, pledges have been made by the UK government that all medicines currently approved under EU law will have their status automatically upheld after Brexit, even if the country ends up leaving the bloc without a formal withdrawal agreement in place. The question of how Britain’s regulatory approach to medicine will evolve from that point remains up for debate, with strong views expressed on both sides.
Many influential bodies within the sector, including the UK BioIndustry Association and the Association of the British Pharmaceutical Industry, have called for pan-European health partnerships and regulatory alignment to be preserved wherever possible to maintain consistent, reliable standards and protect patient safety. However, the British government is keen to explore the opportunity to introduce UK-specific conditions to medicine regulations, affecting, for example, the criteria by which medicines are deemed to qualify for orphan drug status.
New hurdles in the pharmaceutical testing process?
Maintaining regulatory alignment with the EU in the field of medicine seems unlikely, unless the next government chooses to adopt a “soft Brexit” policy, hence why most drugmakers are currently preparing for Brexit with the expectation that it will bring some level of change to the drug testing and approval processes to which they are accustomed.
In the short term, the biggest concern remains that the UK will leave the EU without a withdrawal agreement in place, throwing the current process by which medicines are approved and traded into doubt and confusion until a new working relationship can be formalised. However, even if a deal is agreed, there are numerous ways in which testing procedures could become more complex and time-consuming than they are under the present centralised EMA system.
At the very least, it is likely that significant amounts of the product labelling used by the sector will need to be amended and updated to comply with new UK-specific requirements. If regulatory divergence increases further in the post-Brexit future, companies may be required to submit their medicines through two different approval processes and meet different QC criteria in order to carry on trading in both the EU and the UK.
This could create significant challenges for the growing number of manufacturers that have been embracing more diversified manufacturing models in recent years. Many, for example, are moving out of the era of one-size-fits-all blockbuster drugs to explore the benefits of personalised, tailored therapies, while plenty of fast-growing contract-based manufacturers base their entire business models on producing a broad range of generic products using the same facilities and equipment.
…the structure of the post-Brexit medicine testing and approvals process is yet to be confirmed”
In both of these cases, new requirements for rigorous testing of multiple products under two separate regulatory frameworks could create significant amounts of red tape, prolonging processes. Moreover, many will be concerned that the ensuing lack of clarity may cause a drop in standards or create ambiguity that could be exploited by counterfeiters, especially if a no-deal Brexit creates a shortage and a rise in emergency demand for medicines.
How established analysis methods can offer certainty and continuity
Given the uncertainty that surrounds so many aspects of Brexit, pharmaceutical companies are looking for ways to ensure their own internal processes are robust and resilient enough to withstand the disruption caused by any potential changes to external industry circumstances.
With product quality and regulatory criteria set to be among the key issues in the spotlight as the industry evolves post-Brexit, it is vital for drugmakers to ensure they are doing all they can to create the safest, purest medicines, using tried-and-tested methodologies that are proven to deliver results in accordance with international standards. As such, the sector’s existing dependence on elemental analysis as a key analytical tool could become more important than ever.
For many years, elemental analysers have provided manufacturers with a reliable method of analysing the microbial integrity of the drugs they create, while preventing cross-contamination between product batches. For example, the total organic carbon (TOC) analysis method is widely accepted as an industry-wide QC gold standard by every major international regulator, including the EMA and MHRA, which suggests that any investment in this technology will continue to yield benefits, no matter how regulations evolve in future.
Using this method, manufacturers are able to identify carbon-containing residues in vessels used in manufacturing to confirm they have been cleaned and decontaminated between batches. This is particularly essential for companies developing different products within the same facilities and by ensuring they are well-equipped with these capabilities, companies will guarantee that their drugs are produced to an extremely high standard, ready for any assessment requirements that emerge after Brexit.
Whatever the eventual outcome of Brexit, pharmaceutical manufacturers need to be preparing for these changes in the same way they always have; by keeping a close eye on the emerging trends, while maintaining their ongoing commitment to the highest standards of product safety, quality, purity and traceability. The road to Brexit continues to be littered with challenges, but by ensuring they have the very best tools and solutions at their disposal to guarantee product quality, they will be able to meet each of these challenges head-on, while retaining the trust of patients and prescribers alike.
About the author
Peter Morgan, at Elementar UK, has expertise which includes extensive first-hand experience of delivering methodological and workflow efficiency improvements in laboratory settings.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.
Thanks for the content! It’s an amazing blog.